The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).
 
Mazie Tsang
Stock and Other Ownership Interests - Atara Biotherapeutics (I); AVEO; Poseida Therapeutics
Other Relationship - National Institute on Aging (Inst)
 
Paul Joseph Hampel
No Relationships to Disclose
 
Kari G. Rabe
No Relationships to Disclose
 
Wei Ding
Consulting or Advisory Role - Alexion Pharmaceuticals (Inst); BeiGene (Inst); Merck (Inst); Octapharma USA (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); DTRM (Inst); Merck (Inst); Octapharma USA (Inst)
 
Jose Francisco Leis
No Relationships to Disclose
 
Saad Kenderian
No Relationships to Disclose
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - BeiGene (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Eli Muchtar
Honoraria - Janssen
Consulting or Advisory Role - Protego Biopharma
 
Amber Koehler
No Relationships to Disclose
 
Curtis A Hanson
No Relationships to Disclose
 
Min Shi
No Relationships to Disclose
 
Susan L. Slager
No Relationships to Disclose
 
Neil E. Kay
Consulting or Advisory Role - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Agios (Inst); AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); Celgene (Inst); CSL Behring; CytomX Therapeutics (Inst); DAVA Pharmaceuticals (Inst); Genentech/Abbvie (Inst); Janssen Biotech (Inst); Juno Therapeutics (Inst); MEI Pharma (Inst); MorphoSys (Inst); Oncotracker (Inst); Pharmacyclics (Inst); Rigel (Inst); Sunesis Pharmaceuticals (Inst); Targeted Oncology (Inst); TG Therapeutics (Inst); Tolero Pharmaceuticals (Inst)
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Celgene; Genentech; MEI Pharma; Pharmacyclics/Janssen; Sunesis Pharmaceuticals; TG Therapeutics; Tolero Pharmaceuticals
 
Sameer Ashok Parikh
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); NovalGen (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); TG Therapeutics (Inst)